PetVivo (NASDAQ:PETV) versus Motus GI (NASDAQ:MOTS) Head-To-Head Survey

Volatility and Risk

PetVivo has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares PetVivo and Motus GI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Motus GI	N/A	N/A	N/A

Valuation and Earnings

This table compares PetVivo and Motus GI”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05 million	25.16	-$10.95 million	($0.40)	-2.36
Motus GI	$319,000.00	0.00	-$12.87 million	($15.64)	N/A

PetVivo has higher revenue and earnings than Motus GI. PetVivo is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

24.5% of PetVivo shares are held by institutional investors. Comparatively, 20.1% of Motus GI shares are held by institutional investors. 10.8% of PetVivo shares are held by company insiders. Comparatively, 0.3% of Motus GI shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

About PetVivo

PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.